Unicycive Therapeutics Appoints Meredith Manning to Board of Directors
Key Highlights
- ➤Meredith Manning appointed to Unicycive Therapeutics (UNCY) Board of Directors
- ➤Manning appointed Chairperson of the Nominating and Corporate Governance Committee
- ➤Unicycive’s recent NDA resubmission advances oxylanthanum carbonate toward potential approval
- ➤Manning led U.S. launch of VYKAT™ XR at Soleno Therapeutics
- ➤Manning contributed to FDA approval and U.S. launch of BESREMi®
Expert Statements
Shalabh Gupta, Chief Executive Officer of Unicycive Therapeutics
“We are very pleased to welcome Meredith to our Board of Directors. Her extensive commercialization experience, track record of building successful biopharmaceutical organizations, and leadership through successful product launches will be invaluable to Unicycive. We look forward to benefiting from Meredith’s strategic insight and first-hand experience as we advance OLC towards potential approval and prepare for the next stage of the Company’s growth.”
Meredith Manning, Board member of Unicycive Therapeutics
“I am honored to join Unicycive’s Board of Directors at such an important time for the Company. With the recent NDA resubmission, Unicycive is advancing toward its goal of bringing oxylanthanum carbonate to patients and preparing for its transition to a commercial-stage company. I look forward to working with Shalabh and the Board to support the Company’s strategy and create long-term value for patients and shareholders.”
MOUNTAIN VIEW, Calif., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (“Unicycive” or the “Company”) (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced the appointment of Meredith Manning, M.B.A., to its Board of Directors.
“We are very pleased to welcome Meredith to our Board of Directors. Her extensive commercialization experience, track record of building successful biopharmaceutical organizations, and leadership through successful product launches will be invaluable to Unicycive,” said Shalabh Gupta, M.D., Chief Executive Officer of Unicycive Therapeutics. “We look forward to benefiting from Meredith’s strategic insight and first-hand experience as we advance OLC towards potential approval and prepare for the next stage of the Company’s growth.”
Get started
Create a free account to read the full story.